Arymo ER Under FDA Review as Pain Treatment


The FDA has accepted Egalet Corporation's new drug application for morphine sulfate extended-release tablets (Arymo ER).

The FDA has accepted Egalet Corporation’s new drug application for morphine sulfate extended-release tablets (Arymo ER).

The tablets are designed to treat patients who have severe pain; need daily, long-term relief; and have inadequate responses to alternative treatment options.

The FDA’s goal date for a decision on the application is October 14, 2016.

The submission was based on data from pharmacokinetic studies that demonstrated bioequivalence of Arymo ER 15 mg, 30 mg, and 60 mg to equivalent doses of MS Contin.

"The acceptance of our new drug application for Arymo ER marks an important and exciting step toward the approval of our first Guardian Technology product candidate," said Jeffrey Dayno, MD, chief medical officer of Egalet, in a press release. "We look forward to working with the FDA during the review process in order to bring this product to market as quickly as possible."

The FDA has stated that it intends to hold an advisory committee meeting to discuss the application from Egalet.

Related Videos
Image credit:  Gorodenkoff |
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin -
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny -
Various healthy foods -- Image credit: New Africa |
LGBTQIA+ pride -- Image credit: lazyllama |
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki |
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba |
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT |
© 2024 MJH Life Sciences

All rights reserved.